Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Letters

• Publication date

  2014-10-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.canlet.2014.07.024PMID 25067787
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular genetics of clear-cell renal cell carcinoma.

  2014cited by this paper
• Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.

  2012cited by this paper
• Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy

  2012cited by this paper
• Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.

  2011cited by this paper
• Tissue-specific therapeutic targeting of p53 in cancer: one size does not fit all.

  2011cited by this paper
• MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility.

  2011cited by this paper
• Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53

  2010cited by this paper
• MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines

  2010cited by this paper
• MDM2 promotes cell motility and invasiveness through a RING‐finger independent mechanism

  2010cited by this paper
• p53 and MDM2 in renal cell carcinoma

  2010cited by this paper
• Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

  2009cited by this paper
• 20 years studying p53 functions in genetically engineered mice

  2009cited by this paper
• Regulation of Expression of the Rat Orthologue of Mouse Double Minute 2 (MDM2) by H2O2-induced Oxidative Stress in Neonatal Rat Cardiac Myocytes

  2009cited by this paper
• Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

  2009cited by this paper
• Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene.

  2009cited by this paper
• MDM2 regulates dihydrofolate reductase activity through monoubiquitination.

  2008cited by this paper
• The concept of neurogenic inflammation

  2008cited by this paper
• p53-independent mechanisms regulate the P2-MDM2 promoter in adult astrocytic tumours

  2008cited by this paper
• Regulation of angiogenic factors by HDM2 in renal cell carcinoma.

  2008cited by this paper
• MDM2 inhibitors for cancer therapy.

  2007cited by this paper
• Targeted molecular therapy for renal cell carcinoma.

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.

  2007cited by this paper
• Renal cancer cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α

  2006cited by this paper
• Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.

  2006cited by this paper
• Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.

  2006cited by this paper
• MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation

  2006cited by this paper
• Regulation of p53 and MDM2 Activity by MTBP

  2005cited by this paper
• MEK-ERK Signaling Controls Hdm2 Oncoprotein Expression by Regulating hdm2 mRNA Export to the Cytoplasm*

  2005cited by this paper
• P53 and prognosis: new insights and further complexity.

  2005cited by this paper
• p53 regulation and function in renal cell carcinoma.

  2005cited by this paper
• Apc deficiency predisposes to renal carcinoma in the mouse

  2005cited by this paper
• Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.

  2004cited by this paper
• Why do cancers have high aerobic glycolysis?

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Elevated content of p53 protein in the absence of p53 gene mutations as a possible prognostic marker for human renal cell tumors

  2004cited by this paper
• p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

  2004cited by this paper
• p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma

  2004cited by this paper
• MDM2, an introduction.

  2003cited by this paper
• Surfing the p53 network

  2000cited by this paper
• mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters.

  2000influential reference
• The p53 Tumor Suppressor Protein Does Not Regulate Expression of Its Own Inhibitor, MDM2, Except under Conditions of Stress

  2000cited by this paper
• Interference with c-myc expression and RB phosphorylation during TNF-mediated growth arrest in human endothelial cells.

  1997cited by this paper
• p53 and HER-2 alterations in renal cell carcinoma.

  1997cited by this paper
• The p53 response to ionising radiation in adult and developing murine tissues.

  1996cited by this paper
• A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

  1995cited by this paper
• Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma.

  1994cited by this paper
• Mutations of the VHL tumour suppressor gene in renal carcinoma

  1994cited by this paper
• Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.

  1994cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• [Origin of cancer cells].

  1956cited by this paper
• On the origin of cancer cells.

  1956cited by this paper

• scXDR: drug response prediction across single-cell datasets via heterogeneous network transfer learning

  2026cites this paper
• EZH2-Mediated PTEN Silencing Promotes AKT-Dependent Afatinib Resistance in Radiation-Resistant Cervical Cancer Cells

  2025cites this paper
• Comprehensive analysis of regulated cell death pathways: intrinsic disorder, protein–protein interactions, and cross-pathway communication

  2025cites this paper
• The potential for senotherapy as a novel approach to extend life quality in veterinary medicine

  2024cites this paper
• Frontier knowledge and future directions of programmed cell death in clear cell renal cell carcinoma

  2024cites this paper
• Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma

  2022cites this paper
• TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies

  2020cites this paper
• Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway

  2020cites this paper
• Model-based optimization of combination protocols for irradiation-insensitive cancers

  2020cites this paper
• Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma

  2020cites this paper
• Resistance of human primary mesenchymal stem cells to cytotoxic effects of nutlin‐3 in vitro

  2020cites this paper
• Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy

  2019cites this paper
• ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma

  2018cites this paper
• The effects of Nutlin‐3 on morphology, cellular proliferation, and apoptosis in rat primary mesenchymal stem cells

  2018cites this paper
• p53 and metabolism: from mechanism to therapeutics

  2018cites this paper
• A Novel Combination Therapy of Cisplatin with a Molecular Promoter for Cancer Treatment

  2017cites this paper
• Synergistic effect of nutlin-3 combined with aspirin in hepatocellular carcinoma HepG2 cells through activation of Bcl-2/Bax signaling pathway

  2017influential citation
• Epigenetic silencing of ASPP1 confers 5‐FU resistance in clear cell renal cell carcinoma by preventing p53 activation

  2017cites this paper
• The MDMX (MDM4) oncoprotein as a therapeutic target and determinant of response to MDM2-p53 binding antagonists in human cancer

  2017cites this paper
• Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors

  2017cites this paper
• Significance of Wild-Type p53 Signaling in Suppressing Apoptosis in Response to Chemical Genotoxic Agents: Impact on Chemotherapy Outcome

  2017cites this paper
• Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma

  2017cites this paper
• Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients

  2016cites this paper
• CROSS-TALK BETWEEN THE TUMOR SUPPRESSORS PAR-4 AND P53

  2015cites this paper
• Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16 E6/E7 for further therapeutic directions in renal cell carcinoma.

  2015cites this paper